Abstract
Plasminogen activator inhibitor type 1 (PAI-1) is an inhibitor of plasmin production. Plasmin can directly or indirectly to degrade cartilage and bone matrix. The PAI-1 HindIII polymorphism has been associated with high PAI-1 plasma levels in myocardial infarction patients and control populations. Furthermore, it has been associated with the angiographic extent of coronary artery disease, but their involvement in other diseases is still uncertain. Here, we assessed the relationship between PAI-1 HindIII polymorphism and PAI-1 plasma levels in rheumatoid arthritis (RA). One hundred and twenty-five RA patients and 132 control subjects (CS) were included. Genotypes were identified by the polymerase chain reaction-restriction fragment length polymorphism technique and PAI-1 plasma levels were quantified using an ELISA kit. Not significant differences in genotype and allele frequencies between both studied groups were observed (P > 0.05). RA patients showed lower PAI-1 plasma levels (18.92 ± 12.94 ng/ml) than CS (23.68 ± 23.38 ng/ml), without significant difference (P = 0.299). However, in RA patients the C/G genotype carriers showed higher PAI-1 plasma levels (23.00 ± 13.81 ng/ml) with respect to C/C (16.77 ± 11.97 ng/ml) and G/G (10.47 ± 7.07 ng/ml) genotype carriers (P = 0.036). The PAI-1 HindIII polymorphism was not associated with RA susceptibility. However, the C/G genotype is associated with high PAI-1 plasma levels in RA patients.
Similar content being viewed by others
References
Firestein GS (2005) Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 11:S39–S44
Worthington J (2005) Investigating the genetic basis of susceptibility to rheumatoid arthritis. J Autoimmun 25:16–20
Smith JB, Haynes MK (2002) Rheumatoid arthritis—a molecular understanding. Ann Intern Med 136:908–922
Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916
Sharma PK, Hota D, Pandhi P (2004) Biologics in rheumatoid arthritis. J Assoc Physicians India 52:231–236
Huber K (2001) Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis 11:183–193
Judex MO, Mueller BM (2005) Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more. Am J Pathol 166:645–647
Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356–361
Lijnen HR (2005) Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 3:35–45
Cesarman-Maus G, Hajjar KA (2005) Molecular mechanisms of fibrinolysis. Br J Haematol 129:307–321
Nordt TK, Lohrmann J, Bode C (2001) Regulation of PAI-1 expression by genetic polymorphisms: impact on atherogenesis. Thromb Res 103:S1–S5
Smolarz B, Romanowicz-Makowska H, Kulig A (2003) Plasminogen activator inhibitor 1 (PAI-1) 1334G/A genetic polymorphism in colorectal cancer. Acta Biochim Pol 50:489–495
Klinger KW, Winqvist R, Riccio A, Andreasen PA, Sartorio R, Nielsen LS, Stuart N, Stanislovitis P, Watkins P, Douglas R et al (1987) Plasminogen activator inhibitor type 1 gene is located at region q21.3–q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 84:8548–8552
Grenett HE, Khan N, Jiang W, Booyse FM (2000) Identification of the HindIII polymorphic site in the PAI-1 gene: analysis of the PAI-1 HindIII polymorphism by PCR. Genet Test 4:65–68
de Moor CH, Meijer H, Lissenden S (2005) Mechanisms of translational control by the 3′ UTR in development and differentiation. Semin Cell Dev Biol 16(1):49–58
Dawson S, Hamsten A, Wiman B, Henney A, Humphries S (1991) Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11:183–190
Torres-Carrillo N, Torres-Carrillo NM, Vázquez-Del Mercado M, Rangel- Villalobos H, Parra-Rojas I, Sánchez-Enríquez S, Muñoz-Valle JF (2008) Distribution of -844 G/A and HindIII C/G PAI-1 polymorphisms and plasma PAI-1 levels in Mexican subjects: comparison of frequencies between populations. Clin Appl Thromb Hemost 14:220–226
Benza RL, Grenett H, Li XN, Reeder VC, Brown SL, Go RC, Hanson KA, Perry GJ, Holman WL, McGiffin DC, Kirk KA, Booyse FM (1998) Gene polymorphisms for PAI-1 are associated with the angiographic extent of coronary artery disease. J Thromb Thrombolysis 5:143–150
Benza RL, Grenett HE, Bourge RC, Kirklin JK, Naftel DC, Castro PF, McGiffin DC, George JF, Booyse FM (1998) Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease. Circulation 98:2248–2254
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
Cardiel MH, Abello-Banfi M, Ruiz-Mercado R, Alarcon-Segovia D (1993) How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clin Exp Rheumatol 11:117–121
Leeb BF, Andel I, Sautner J, Bogdan M, Maktari A, Nothnagl T, Rintelen B (2005) Disease activity measurement of rheumatoid arthritis: comparison of the simplified disease activity index (SDAI) and the disease activity score including 28 joints (DAS28) in daily routine. Arthritis Rheum 53:56–60
Ruiz-Quezada S, Vázquez-Del Mercado M, Parra-Rojas I, Rangel-Villalobos H, Best-Aguilera C, Sánchez-Orozco LV, Muñoz-Valle JF (2004) Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico: association with biochemical and hematological parameters. Ann Genet 47:155–162
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
Snow MH, Mikuls TR (2005) Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 17:234–241
Acknowledgments
This work was supported by grant no. 45703-M to JFMV of the National Council of Science and Technology (CONACyT, México-Universidad de Guadalajara).
Conflict of interest statement
The authors declare that they have no conflict of interest related to the publication of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Torres-Carrillo, N., Torres-Carrillo, N.M., Martínez-Bonilla, G.E. et al. Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis. Clin Exp Med 9, 223–228 (2009). https://doi.org/10.1007/s10238-009-0038-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10238-009-0038-0